EPS for Soligenix, Inc. (SNGX) Expected At $-0.28

July 14, 2018 - By Mark Mitchell

Soligenix, Inc. (NASDAQ:SNGX) Logo

Analysts expect Soligenix, Inc. (NASDAQ:SNGX) to report $-0.28 EPS on August, 10.They anticipate $0.13 EPS change or 31.71 % from last quarter’s $-0.41 EPS. After having $-0.27 EPS previously, Soligenix, Inc.’s analysts see 3.70 % EPS growth. It closed at $1.04 lastly. It is down 32.77% since July 14, 2017 and is downtrending. It has underperformed by 45.34% the S&P500.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company has market cap of $17.18 million. It operates through two divisions, BioTherapeutics and Vaccines/BioDefense. It currently has negative earnings. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.

More notable recent Soligenix, Inc. (NASDAQ:SNGX) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” on June 26, 2018, also Benzinga.com with their article: “28 Stocks Moving In Monday’s Mid-Day Session” published on July 09, 2018, Seekingalpha.com published: “Soligenix receives European and Canadian patents for its ricin toxin vaccine formulation, Shares up 5.7% premarket” on July 09, 2018. More interesting news about Soligenix, Inc. (NASDAQ:SNGX) were released by: Seekingalpha.com and their article: “Soligenix prices $8M public offering” published on June 28, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: FDA Greenlights Tandem Diabetes’ Insulin Pump, More IPOs On Tap” with publication date: June 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.